Drug intelligence / Profile preview

RIST5122

Development stage: Unknown
Lead developer: Aristea Therapeutics
Modality: Small Molecules

Overview

**RIST5122** is a small molecule CXCR2 antagonist developed by Aristea Therapeutics, Inc., designed to block the C-X-C motif chemokine receptor 2 (CXCR2), which plays a key role in neutrophil recruitment and inflammation. It was part of Aristea's pipeline alongside other CXCR2 inhibitors like RIST4721, targeting inflammatory conditions through suppression of CXCR2-mediated signaling, though specific indications remained undisclosed.[1][3]

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)

Beyond the preview

Go deeper on RIST5122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIST5122.

Explore the full profile